Vanguard realigns holdings; Charles River (NYSE: CRL) shows 0% stake
Rhea-AI Filing Summary
Charles River Laboratories International, Inc. Schedule 13G/A: The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment. The filing explains certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed by the Head of Global Fund Administration on 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated its reporting and now reports no beneficial ownership in Charles River.
The filing documents an internal realignment at The Vanguard Group effective 01/12/2026, after which certain subsidiaries report holdings separately under SEC Release No. 34-39538. The statement clarifies that Vanguard no longer is deemed to beneficially own securities reported by those subsidiaries.
Cash‑flow treatment and any trading plans are not disclosed in the excerpt; subsequent filings by Vanguard subsidiaries may show holdings. Impact on Charles River's shareholder base depends on reported positions from those subsidiaries.
FAQ
What does the Schedule 13G/A filed by Vanguard for CRL state?
When did Vanguard's internal realignment take effect in the filing?
Who signed the Schedule 13G/A amendment for Vanguard for CRL?
Does the filing show any voting or dispositive power for Vanguard over CRL shares?
Will this filing change Charles River's public shareholder count or control?